GLORIA-AF Registry Program (Phase II/III)

N/ACompletedNCT01937377

Boehringer Ingelheim200 enrolled

Overview

In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into three protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, 1160.136 for EU and EEA countries and 1160.171 for Switzerland. The total number of patients enrolled in three protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Stroke Atrial Fibrillation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: 1\) Patients newly diagnosed with non-valvular atrial fibrillation (NVAF) at risk for stroke. Further inclusion criteria apply Exclusion criteria: 1. Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention; 2. Patients who have received more than 60 days of vitamin K antagonist (VKA) treatment in their lifetime; 3. AF with a generally reversible cause; 4. Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (for example, a VKA) is indicated. Further exclusion criteria apply

Locations (5)

University Hospital Basel

Basel, Switzerland

CHUV - Centre hospitalier universitaire vaudois

Lausanne, Switzerland

Cardiocentro Ticino

Lugano, Switzerland

Kantonsspital St.Gallen

Sankt Gallen, Switzerland